clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Boutonneuse Fever D001907 5 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Whooping Cough D014917 6 associated lipids
Bronchitis D001991 6 associated lipids
Stomach Diseases D013272 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Bacteriuria D001437 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Metaplasia D008679 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Leprosy D007918 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urination Disorders D014555 9 associated lipids
Urethritis D014526 9 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Pancreatitis D010195 10 associated lipids
Dyspnea D004417 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Influenza, Human D007251 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Otitis Media D010033 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Radiation Injuries D011832 14 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Dermatomycoses D003881 17 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Peptic Ulcer D010437 19 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kruppa A et al. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. 1998 Dermatology (Basel) pmid:9621142
Ishii K et al. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. 1998 Drug Dev Ind Pharm pmid:15605442
Highleyman L FDA issues Hismanal warning. Food and Drug Administration. 1998 BETA pmid:11365263
Al-Sibai MB et al. Ocular penetration of oral clarithromycin in humans. 1998 J Ocul Pharmacol Ther pmid:9867340
Wallace RJ and Brown BA Catheter sepsis due to Mycobacterium chelonae. 1998 J. Clin. Microbiol. pmid:9867491
Shafran SD et al. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group. 1998 Clin. Infect. Dis. pmid:9868650
van Westrhenen R et al. Pneumonia and glomerulonephritis caused by Mycoplasma pneumoniae. 1998 Nephrol. Dial. Transplant. pmid:9870493
Niang M et al. [Painful nodular lesions]. 1998 Rev Med Interne pmid:9793156
Saika T et al. [A mechanism of clarithromycin resistance in Helicobacter pylori]. 1998 Kansenshogaku Zasshi pmid:9796191
Abouesh A and Hobbs WR Clarithromycin-induced mania. 1998 Am J Psychiatry pmid:9812131
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Louw JA et al. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9768531
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Sackoff J et al. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. 1998 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:9833748
Laine L et al. Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. 1998 Aliment. Pharmacol. Ther. pmid:9768532
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Mukunda BN et al. Clarithromycin therapy for bacillary peliosis did not prevent bacillary angiomatosis. 1998 Clin. Infect. Dis. pmid:9770180
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Hawkey CJ et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. 1998 Lancet pmid:9759744
Fennerty MB Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. 1998 Am. J. Gastroenterol. pmid:9448162
Forné M et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. 1998 Am. J. Gastroenterol. pmid:9448170
Sax L Bacterial pharyngitis in children. 1998 J Fam Pract pmid:9451356
Sevin E et al. Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR. 1998 FEMS Microbiol. Lett. pmid:9742711
Hiratsuka T et al. [Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone]. 1998 Nihon Kokyuki Gakkai Zasshi pmid:9742869
Lygren I et al. [Treatment of Helicobacter pylori infection]. 1998 Tidsskr. Nor. Laegeforen. pmid:9889634
Einarson A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. 1998 Am J Perinatol pmid:9890248
Tsuneoka H et al. [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. 1998 Kansenshogaku Zasshi pmid:9621560
Abe M et al. A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. 1998 Respir Med pmid:9893782
Amsden GW et al. Oral cimetidine prolongs clarithromycin absorption. 1998 Antimicrob. Agents Chemother. pmid:9660986
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
Warheker PT et al. Successful treatment of saccular endophthalmitis with clarithromycin. 1998 Eye (Lond) pmid:10326009
Bazzoli F et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. 1998 Aliment. Pharmacol. Ther. pmid:9663723
Pozzato P et al. Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9663724
Bocheńska-Marciniak M et al. [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. 1998 Pol. Arch. Med. Wewn. pmid:10335027
Griffith DE Mycobacteria as pathogens of respiratory infection. 1998 Infect. Dis. Clin. North Am. pmid:9779380
Casswall TH et al. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. 1998 J. Pediatr. Gastroenterol. Nutr. pmid:9779970
Aberg JA et al. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. 1998 J. Infect. Dis. pmid:9780266
Berry V et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. 1998 Antimicrob. Agents Chemother. pmid:9835514
Butt AA Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. 1998 Am. J. Med. Sci. pmid:9427575
Sonnenberg A et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. 1998 Arch. Intern. Med. pmid:9570170
Dal Bo' N et al. Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? 1998 J. Gastroenterol. Hepatol. pmid:9570242
Trevisani L et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. 1998 Am. J. Gastroenterol. pmid:9517646
O'Connor HJ et al. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? 1998 Aliment. Pharmacol. Ther. pmid:9570262
Scott BB Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9570263
Jarboe E et al. Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. 1998 Diagn. Microbiol. Infect. Dis. pmid:9572027
Treiber G et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. 1998 Helicobacter pmid:9546119
Preston SL et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. 1998 AIDS pmid:9468380
Suzuki J et al. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. 1998 Helicobacter pmid:9546120
Lindsetmo RO et al. Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. 1998 Scand. J. Gastroenterol. pmid:9548613
Comet R et al. [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. 1998 Gastroenterol Hepatol pmid:9549183
Carnicer J [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. 1998 Gastroenterol Hepatol pmid:9549199
Kato S et al. Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. 1998 Helicobacter pmid:9844069
Gisbert JP et al. [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. 1998 Rev Clin Esp pmid:9844453
Gisbert JP et al. [Role of pantoprazole in the eradicating treatment of Helicobacter pylori]. 1998 Rev Clin Esp pmid:9844458
Gudjonsson H et al. High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9845401
Murata H et al. Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. 1998 Am. J. Gastroenterol. pmid:9820380
Laine L et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. 1998 Am. J. Gastroenterol. pmid:9820381
Kaeser YA et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. 1998 Am J Health Syst Pharm pmid:9825040
Sakamoto M et al. [Efficacy of clarithromycin (CAM) in patients with inoperable non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597485
Teramoto S et al. [Effect of clarithromycin administration on interferon-gamma and interleukin 12 mRNA expression in the tumor tissue of non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597486
Ueta K et al. [Evaluation of BRM (biological response modifier) action of clarithromycin (CAM)--effect on cytokine expression in a mouse lung cancer model]. 1998 Jpn J Antibiot pmid:9597487
Kokubo Y et al. [Effect of clarithromycin on experimental pulmonary metastasis]. 1998 Jpn J Antibiot pmid:9597488
Yano S et al. [Significance of therapeutic efficacy of clarithromycin in a model for human lung cancer metastasis and a mouse tumor system]. 1998 Jpn J Antibiot pmid:9597491
Sasa K et al. [Antineoplastic therapeutic effect of clarithromycin in rats]. 1998 Jpn J Antibiot pmid:9597492
Miyamoto N et al. [Test to set dosages for long-term administration of clarithromycin to treat chronic paranasal sinusitis]. 1998 Jpn J Antibiot pmid:9597498
Perng CL et al. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. 1998 Dig. Dis. Sci. pmid:9539638
Fujita K et al. [Neutrophil count and IL-8 level of nasal secretion of patients with chronic paranasal sinusitis and the effects of macrolide antibiotics]. 1998 Jpn J Antibiot pmid:9597505
Scheen AJ [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. 1998 Rev Med Liege pmid:9555183
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Goujard C et al. Clarithromycin-resistant Mycobacterium avium strain in a clarithromycin-naive AIDS patient. 1998 Clin. Infect. Dis. pmid:9455532
Williamson R et al. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. 1998 Scand. J. Gastroenterol. Suppl. pmid:9515751
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. 1998 Am. J. Gastroenterol. pmid:9517644
Adamek RJ et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. 1998 Am. J. Gastroenterol. pmid:9517645
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. 1998 Antimicrob. Agents Chemother. pmid:9517944
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Fattorini L et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. 1998 Antimicrob. Agents Chemother. pmid:9517960
Sheu BS et al. One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. 1998 J. Formos. Med. Assoc. pmid:9585678
Hasegawa M et al. [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. 1998 Kansenshogaku Zasshi pmid:9585692
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Lacy MK et al. Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. 1998 Int. J. Antimicrob. Agents pmid:9916901
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Fera MT et al. Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. 1998 Int. J. Antimicrob. Agents pmid:9916902
Roussel G and Igual J Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. 1998 Int. J. Tuberc. Lung Dis. pmid:9626603
Archimandritis A et al. Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. 1998 J. Intern. Med. pmid:9627163
Petersen AM et al. [Resistance of Helicobacter pylori to clarithomycin]. 1998 Ugeskr. Laeg. pmid:9627511
Domingo D et al. High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. 1998 J. Antimicrob. Chemother. pmid:9630414
Cecchi R and Torelli E Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. 1998 J. Dermatol. pmid:9714985
Dore MP et al. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. 1998 Clin. Infect. Dis. pmid:9675458
Dunne EF et al. Streptomyces pneumonia in a patient with human immunodeficiency virus infection: case report and review of the literature on invasive streptomyces infections. 1998 Clin. Infect. Dis. pmid:9675460
Ward TT et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. 1998 Clin. Infect. Dis. pmid:9827282
Wakasugi H et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. 1998 Clin. Pharmacol. Ther. pmid:9695727
Hsieh PF et al. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori. 1998 J. Formos. Med. Assoc. pmid:9700240
Ellenrieder V et al. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9701524
Burman WJ et al. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. 1998 Diagn. Microbiol. Infect. Dis. pmid:9635911
Nordt SP et al. Clarithromycin induced digoxin toxicity. 1998 J Accid Emerg Med pmid:9639187
Gray VS Syncopal episodes associated with cisapride and concurrent drugs. 1998 Ann Pharmacother pmid:9640482
Grove DI et al. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. 1998 Pathology pmid:9643503
Makhani S et al. Atypical cervico-facial mycobacterial infections in childhood. 1998 Br J Oral Maxillofac Surg pmid:9643597